CAR T‑Cell Therapy in New Zealand: When Will Blood Cancer Patients Get Access?

In recent years, CAR T‑cell therapy has moved from the realm of clinical trials to a living, breathing cancer treatment that has saved lives worldwide. Yet, for patients in New Zealand, the journey from research to routine care is still unfolding. This article breaks down the current landscape, funding status, eligibility criteria, and what you can do to stay informed.

What Is CAR T‑Cell Therapy?

CAR T‑cell therapy is an immune‑cell engineering technique that actively re‑tools a patient’s own T cells to fight cancer cells. It’s become a frontline option for certain relapsed or refractory blood cancers, including:

• Acute lymphoblastic leukaemia (ALL)
• Diffuse large B‑cell lymphoma (DLBCL)
• Multiple myeloma (MM)

Unlike traditional chemo or radiation, CAR T therapy offers a one‑time infusion that can induce durable remissions in a significant proportion of patients.

Why Is New Zealand Behind the Global Curve?

Multiple factors delay widespread adoption:

1. High Cost – A single CAR T infusion can run from NZ$400,000 to NZ$600,000 in global markets. Pricing negotiations with manufacturers and the cost of supportive care (e.g., ICU stays for cytokine release syndrome) add complexity.
2. Limited Capacity – Only a handful of New Zealand hospitals (e.g., Wellington’s National Haematology Center) have the expertise and infrastructure to run CAR T programs.
3. Regulatory Pathways – The New Zealand Ministry of Health (MOH) requires robust evidence of safety and effectiveness for new treatments, often necessitating a New Zealand‑specific clinical study.
4. Funding Framework – The Pharmaceutical Management Agency (Pharmac) must demonstrate that a drug is cost‑effective relative to existing options before it can be subsidised under the Pharmaceutical Benefit Scheme (PBS).

Recent Milestones in Try‑and‑Banks

In 2023, the MOH announced a provisional funding decision for CAR T therapy for Acute Lymphoblastic Leukaemia in patients under 18, with an estimated subsidy of NZ$450,000 per patient. This first step is a major leap forward, but it is limited to a single indication and age group.

Meanwhile, two multinational companies – Novartis (tisagenlecleucel) and Bristol‑Myers Squibb (axicabtagene ciloleucel) – have entered negotiations to bring their products to a broader New Zealand market. These discussions hinge on clinical trial data from Australian sites and a risk‑sharing agreement that addresses the potential long‑term cost savings of successful treatment.

How Does a Patient Qualify?

The eligibility criteria under the Pharmac guidelines are strict, focusing on :

• Patients who have relapsed or refractory disease after at least two rounds of standard therapy
• Patients whose disease is biologically amenable to CAR T (e.g., CD19 positive B‑cell malignancies)
• Age limits varying by drug brand – typically 1–70 years for ALL, and 18+ for lymphoma and myeloma
• A comprehensive pre‑infusion assessment that rules out uncontrolled infection or organ dysfunction

Because of these restrictions, many patients’ families often wonder when the treatment will be “available for everyone.” The short answer is: not yet. But the timelines are improving.

Pharmac Review Process – The Road to PBS Listing

When a manufacturer submits a dossier, Pharmac performs a rigorous review:

1. Initial Assessment – Evaluates safety, clinical benefit, and preliminary cost data.
2. Extended Review – Requires additional data from local studies or a demonstrated risk‑sharing arrangement.
3. Decision – If approved, the drug is added to the PBS; if not, the manufacturer can withdraw or re‑apply.

Pharmac typically completes a full review within 12–18 months, but complex therapies like CAR T can see extended timelines due to emerging safety data from real‑world use.

What the 2024 Forecast Looks Like

Based on current progress, here’s a realistic time‑line for patients outside the pediatric ALL cohort:

• Late 2024 – Potential PBS listing for tisagenlecleucel in adult DLBCL (conditional)
• Mid‑2025 – Subsidised access for axicabtagene ciloleucel in relapsed multiple myeloma (pending negotiations)
• 2025–2026 – Expansion to other B‑cell lymphomas and Hodgkin lymphoma, as data accumulate

These dates are optimistic and depend on:

• Successful final trials in the New Zealand population
• Positive risk‑sharing contracts with manufacturers
• Continued availability of high‑capacity infusion and post‑care centres

How to Stay Informed and Prepared

Patients and caregivers can take proactive steps to accelerate access:

1. Consult your leukaemia/lymphoma specialist – they will be the first to know when a treatment is approved for your condition.
2. Join patient advocacy groups such as Cancer Society New Zealand and American Leukemia & Leukemia (NZ chapters) for real‑time updates.
3. Keep a copy of the latest Pharmac statements handy – they publish an annual review of subsidised treatments.
4. Consider participating in a clinical trial if eligible; this can provide both early access and contribute to the evidence base.
5. Explore patient assistance programmes from drug manufacturers – some cover a portion of the cost if you are not yet subsidised.

Conclusion: Hope on the Horizon, but Patience is Key

CAR T‑cell therapy represents a seismic shift in the battle against blood cancers. While New Zealand patients can already benefit from the first subsidised program for pediatric ALL, the broader rollout will take a few more years. By staying informed, engaging with healthcare specialists, and advocating for faster access, patients and families can position themselves for the best possible chance at life‑saving treatment.

For more updates, subscribe to our newsletter and join the conversation on our Facebook and Twitter pages.